Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Summarization of the New Perspective

Speciality: Hematology


Speaker:

Prof. Dr. Carsten Schmidt | MA, FEBGH Department of Internal Medicine (Gastroenterology, Metabolic Diseases), Fulda Hospital

Description:

A warm welcome to all the medical professionals to this session on "Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Summarization of the New Perspective." This session synthesizes the key takeaways from our discussion on ferric maltol, highlighting its transformative potential in the management of iron deficiency anemia (IDA). The overarching new perspective is a shift away from the traditional, one-size-fits-all approach to oral iron supplementation, toward a more nuanced and patient-focused strategy.

The primary limitation of standard oral iron salts is their high incidence of gastrointestinal (GI) side effects, which leads to poor patient adherence and treatment failure. Ferric maltol provides a new perspective by addressing this issue directly. Its unique chemical structure, a stable complex of ferric iron (Fe³⁺) and maltol, minimizes the release of free iron in the gut, thereby reducing GI irritation and inflammation. This improved tolerability is not just a secondary benefit; it is a core feature that can lead to better treatment compliance and, ultimately, more effective iron repletion.

In conclusion, the new perspective is that ferric maltol is not simply another oral iron option, but a clinically meaningful alternative that overcomes the historical drawbacks of traditional oral iron. Its proven efficacy and favorable tolerability profile, particularly in challenging patient populations like those with inflammatory bowel disease or chronic kidney disease, position it as a valuable tool in the modern management of IDA. This allows clinicians to choose a therapy that is both effective and well-tolerated from the outset, leading to a better quality of life for patients.


See More Webinars @ Hidoc Webinars




Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

MRD-Guided Azacitidine May Delay Relapse in AML, MDS

2.

According to JAMA, women who have false-positive mammogram results are at a higher risk of developing breast cancer over time.

3.

COVID-19 mRNA vaccines could unlock the next revolution in cancer treatment

4.

It has been discovered that personalized dosing in the treatment of prostate cancer improves patient outcomes.

5.

Both men and women who receive the HPV vaccine have a lower risk of developing multiple cancer types.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot